CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 25 enrolled
Drug / intervention
PembroRTdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03523702
NCT03523702Phase 2Completed
CompareCT.gov

The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial (SPRINT)

Montefiore Medical Center·interventional·Posted May 14, 2018·Updated Apr 9, 2026

In Brief

A Phase 2 clinical trial evaluating PembroRT for Non-small Cell Lung Cancer, NSCLC. Completed, enrolled 25 participants across 1 site.

Detailed Summary

The goal of this study is to explore if, for locally advanced non-small cell lung cancer patients whose tumors have high levels of PD-L1 (a marker associated with benefits from immunotherapy), a combination of immunotherapy and a personalized 4-week radiotherapy course could be more effective than standard treatment, which is a combination of chemotherapy and radiotherapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer, NSCLC
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC, University of Michigan, New York University, Henry Ford Cancer Institute

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedMay 14, 2018
Enrollment StartAug 30, 2018
Primary CompletionNov 18, 2022
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 8.1 years ago

Interventions

PembroRTdrug

Patients whose tumors are found to have high (≥ 50%) PD-L1 expression will automatically be placed in the PembroRT group. These patients will receive three intravenous treatments with pembrolizumab, followed by four weeks of daily radiotherapy, followed by up to 12 more treatments with pembrolizumab. Pembrolizumab is given as an intravenous infusion once every three weeks. This treatment course will last, in total, up to one year. Patients whose tumors are found to have low (\< 50%) PD-L1 will be treated with a standard-o-care regimen and not be a part of this clinical trial.